Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Chembio Diagnostics Inc. (CEMI)

5.91   0.02 (0.34%) 01-17 17:32
Open: 6.05 Pre. Close: 5.89
High: 6.08 Low: 5.62
Volume: 1,619,362 Market Cap: 119M
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, Dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and Shire Human Genetic Therapies, Inc. to develop a novel POC diagnostic test. It also has a strategic partnership with LumiraDx Limited to develop point-of-care diagnostic tests for the detection of the COVID-19 virus, and IgM and IgG antibodies on the LumiraDx and Chembio DPP platforms. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Hauppauge, New York.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 6.087 - 6.11 6.11 - 6.128
Low: 5.562 - 5.589 5.589 - 5.611
Close: 5.868 - 5.911 5.911 - 5.946

Technical analysis

as of: 2021-01-15 4:38:41 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 7.70     One year: 8.99
Support: Support1: 5.37    Support2: 4.62
Resistance: Resistance1: 6.59    Resistance2: 7.70
Pivot: 5.19
Moving Average: MA(5): 5.59     MA(20): 5.25
MA(100): 4.95     MA(250): 5.91
MACD: MACD(12,26): 0.04     Signal(9): -0.05
Stochastic oscillator: %K(14,3): 69.24     %D(3): 71.40
RSI: RSI(14): 60.11
52-week: High: 15.89  Low: 2.25  Change(%): 47.0
Average Vol(K): 3-Month: 157516  10-Days: 121241

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
CEMI has closed above the upper band by 1.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 7.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Sat, 16 Jan 2021
Is Chembio Diagnostics, Inc.'s (NASDAQ:CEMI) Shareholder Ownership Skewed Towards Insiders? - Simply Wall St

Thu, 14 Jan 2021
Thinking about buying stock in Express, Nantkwest, Gevo, Canopy Growth Corp, or Chembio Diagnostics? - PRNewswire

Thu, 14 Jan 2021
BUZZ-U.S. STOCKS ON THE MOVE-China tech giants, NantKwest, Chembio Diagnostics, Delta Air Lines - Nasdaq

Thu, 14 Jan 2021
Premarket Mover: Chembio Diagnostics Inc (CEMI) Up 12.80% - InvestorsObserver

Thu, 14 Jan 2021
Chembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test Systems - GlobeNewswire

Sun, 03 Jan 2021
Chembio Diagnostics - Consensus Indicates Potential 84.4% Upside - DirectorsTalk Interviews

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Diagnostics & Research
Shares Out. (M) 20
Shares Float (M) 18
% Held by Insiders 13.89
% Held by Institutions 33.75
Shares Short (K) 3,870
Shares Short P. Month (K) 4,140

Stock Financials

EPS -1.220
EPS Est This Year -0.520
EPS Est Next Year -0.200
Book Value (p.s.) 1.680
Profit Margin -76.55
Operating Margin -63.26
Return on Assets (ttm) -18.1
Return on Equity (ttm) -74.6
Qtrly Rev. Growth 5.7
Gross Profit (p.s.) 0.175
Sales Per Share 1.442
EBITDA (p.s.) -0.811
Qtrly Earnings Growth
Operating Cash Flow (M) -17
Levered Free Cash Flow (M) -12

Stock Valuations

PE Ratio -4.84
PEG Ratio
Price to Book value 3.52
Price to Sales 4.10
Price to Cash Flow -7.10

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.